杜鲁特格拉维尔
医学
阿巴卡韦
拉米夫定
恩曲他滨
耐受性
药理学
固定剂量组合
整合酶抑制剂
人类免疫缺陷病毒(HIV)
病毒学
病毒载量
抗逆转录病毒疗法
不利影响
乙型肝炎病毒
病毒
作者
Brandon L Christensen,Darrell Tan
标识
DOI:10.1080/14656566.2022.2029409
摘要
There are more than 30 agents available for the treatment of HIV with guidelines shifting toward integrase strand transfer inhibitors (INSTIs) as part of first line therapy. The fixed dose combination of dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC) is a convenient, well tolerated, and highly effective option for treating HIV infection and remains a first line therapy across several prominent guidelines.In this drug evaluation, the authors provide a comprehensive overview of DTG/ABC/3TC for the treatment of HIV including the pharmacokinetics, pharmacodynamics, efficacy, safety, and tolerability. The authors also provide the reader with their expert perspectives on this particular treatment strategy.While DTG/ABC/3TC remains a valuable HIV treatment option, newer combination regimens have entered the market. Bictegravir with tenofovir alafenamide and emtricitabine offers the benefit of same day initiation and efficacy in hepatitis B co-infection, while new two-drug regimens enhance the simplicity of HIV treatment. Continued study is required into the mechanisms and optimal management strategies for weight gain for many regimens, including DTG/ABC/3TC.
科研通智能强力驱动
Strongly Powered by AbleSci AI